Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen
Journal article published in 2006 by
M. Martín,
A. Lluch 
,
M. A. Seguí,
A. Ruiz,
M. Ramos,
E. Adrover,
Á. Rodríguez-Lescure,
R. Grosse,
L. Calvo ,
C. Fernandez-Chacón,
M. Roset,
A. Antón,
D. Isla ,
P. Martínez del Prado,
L. Iglesias
and other authors.
,
M. A. Seguí,
A. Ruiz,
M. Ramos,
E. Adrover,
Á. Rodríguez-Lescure,
R. Grosse,
L. Calvo ,
C. Fernandez-Chacón,
M. Roset,
A. Antón,
D. Isla ,
P. Martínez del Prado,
L. Iglesias
and other authors.
This paper is available in a repository.
Full text: Download
Published version:
archiving forbidden
Data provided by 